Adoram Therapeutics SA

Swiss Biotech Association

Member

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).

Location

Chemin des Semailles 50, 1212 Grand-Lancy, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2022
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Altorfer Engineering GmbH

Altorfer Engineering is a contractor and consulting company with expertise in providing engineering and project management services, due diligence assessments as well as technology transfer for aseptic drug product and biologics processes.
6300 Zug

Member

ATLyphe AG

ATLyphe is a Swiss biotech startup with the goal of developing antibody-based solutions engaging T cells for precision immunotherapy. We aim to not only provide less toxic and more precise treatments for current patients but also increase the total number of patients eligible to receive the therapy.
8006 Zürich

Member

Blueprint Medicines (Switzerland GmbH)

Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, our medicines selectively target genetic drivers, with the goal of staying one step ahead of disease.
6300 Zug

Member